株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

原発性硬化性胆管炎:パイプライン分析

Primary Sclerosing Cholangitis - Pipeline Review, H1 2019

発行 Global Markets Direct 商品コード 246021
出版日 ページ情報 英文 115 Pages
即納可能
価格
本日の銀行送金レート: 1USD=112.86円で換算しております。
Back to Top
原発性硬化性胆管炎:パイプライン分析 Primary Sclerosing Cholangitis - Pipeline Review, H1 2019
出版日: 2019年02月01日 ページ情報: 英文 115 Pages
概要

原発性硬化性胆管炎(PSC)は慢性の肝臓疾患で、炎症を伴う進行性の胆汁鬱滞や、肝内・肝外の総肝胆管の線維化といった特徴があります。主な症状として、腹痛や悪寒、下痢、倦怠感、痒み、体重減少などが挙げられます。主な疾病素質には、年齢や炎症性腸疾患などが含まれています。また、主な治療法として、抗生物質や抗ヒスタミン剤、胆汁酸結合剤などがあります。

当レポートでは、世界各国での原発性硬化性胆管炎(PSC)治療用のパイプライン製品の開発状況について分析し、パイプライン製品の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などを調査して、その結果を概略以下の構成でお届けします。

目次

イントロダクション

  • 分析範囲

原発性硬化性胆管炎の概要

治療薬の開発

  • 原発性硬化性胆管炎向けパイプライン製品:概要
  • 原発性硬化性胆管炎向けパイプライン製品:比較分析

企業で開発中の治療薬

パイプライン製品の概況

  • 臨床段階の製品

企業で開発中の製品

治療薬開発に従事している企業

  • Biotie Therapies Corp.
  • ChemoCentryx, Inc.
  • Dr. Falk Pharma GmbH
  • Gilead Sciences, Inc.
  • Intercept Pharmaceuticals, Inc.
  • Shire Plc

治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • BTT-1023
  • CCX-507
  • norursodeoxycholic acid
  • obeticholic acid
  • SHP-625
  • simtuzumab

最新パイプライン動向

製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表一覧

図表

List of Tables

  • Number of Products under Development for Primary Sclerosing Cholangitis, H1 2019
  • Number of Products under Development by Companies, H1 2019
  • Products under Development by Companies, H1 2019
  • Products under Development by Companies, H1 2019 (Contd..1), H1 2019
  • Number of Products by Stage and Target, H1 2019
  • Number of Products by Stage and Mechanism of Action, H1 2019
  • Number of Products by Stage and Route of Administration, H1 2019
  • Number of Products by Stage and Molecule Type, H1 2019
  • Primary Sclerosing Cholangitis - Pipeline by Acorda Therapeutics Inc, H1 2019
  • Primary Sclerosing Cholangitis - Pipeline by Albireo Pharma Inc, H1 2019
  • Primary Sclerosing Cholangitis - Pipeline by Allergan Plc, H1 2019
  • Primary Sclerosing Cholangitis - Pipeline by Conatus Pharmaceuticals Inc, H1 2019
  • Primary Sclerosing Cholangitis - Pipeline by Dr. Falk Pharma GmbH, H1 2019
  • Primary Sclerosing Cholangitis - Pipeline by Gilead Sciences Inc, H1 2019
  • Primary Sclerosing Cholangitis - Pipeline by Intercept Pharmaceuticals Inc, H1 2019
  • Primary Sclerosing Cholangitis - Pipeline by NGM Biopharmaceuticals Inc, H1 2019
  • Primary Sclerosing Cholangitis - Pipeline by Nyrada Inc, H1 2019
  • Primary Sclerosing Cholangitis - Pipeline by Pliant Therapeutics Inc, H1 2019
  • Primary Sclerosing Cholangitis - Pipeline by Sancilio & Company Inc, H1 2019
  • Primary Sclerosing Cholangitis - Pipeline by Seres Therapeutics Inc, H1 2019
  • Primary Sclerosing Cholangitis - Pipeline by Shenzhen HighTide Biopharmaceutical Ltd, H1 2019
  • Primary Sclerosing Cholangitis - Pipeline by Sirnaomics Inc, H1 2019
  • Primary Sclerosing Cholangitis - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2019
  • Primary Sclerosing Cholangitis - Dormant Projects, H1 2019
  • Primary Sclerosing Cholangitis - Discontinued Products, H1 2019

List of Figures

  • Number of Products under Development for Primary Sclerosing Cholangitis, H1 2019
  • Number of Products under Development by Companies, H1 2019
  • Number of Products by Top 10 Targets, H1 2019
  • Number of Products by Stage and Top 10 Targets, H1 2019
  • Number of Products by Top 10 Mechanism of Actions, H1 2019
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019
  • Number of Products by Routes of Administration, H1 2019
  • Number of Products by Stage and Routes of Administration, H1 2019
  • Number of Products by Molecule Types, H1 2019
  • Number of Products by Stage and Molecule Types, H1 2019
目次
Product Code: GMDHC11059IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Primary Sclerosing Cholangitis - Pipeline Review, H1 2019, provides an overview of the Primary Sclerosing Cholangitis (Gastrointestinal) pipeline landscape.

Primary sclerosing cholangitis (PSC) is a chronic liver disease characterized by a progressive course of cholestasis with inflammation and fibrosis of the intrahepatic and extra hepatic bile ducts. Symptoms include abdominal pain, chills, diarrhea, fatigue, itchiness and weight loss. The predisposing factors include age and inflammatory bowel diseases. Treatment includes antibiotics and bile-acid-binding drugs.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Primary Sclerosing Cholangitis - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Primary Sclerosing Cholangitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Primary Sclerosing Cholangitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Primary Sclerosing Cholangitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 8, 2, 11 and 1 respectively.

Primary Sclerosing Cholangitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Primary Sclerosing Cholangitis (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Primary Sclerosing Cholangitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Primary Sclerosing Cholangitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Primary Sclerosing Cholangitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Primary Sclerosing Cholangitis (Gastrointestinal)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Primary Sclerosing Cholangitis (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Primary Sclerosing Cholangitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Primary Sclerosing Cholangitis - Overview
  • Primary Sclerosing Cholangitis - Therapeutics Development
  • Primary Sclerosing Cholangitis - Therapeutics Assessment
  • Primary Sclerosing Cholangitis - Companies Involved in Therapeutics Development
  • Primary Sclerosing Cholangitis - Drug Profiles
  • Primary Sclerosing Cholangitis - Dormant Projects
  • Primary Sclerosing Cholangitis - Discontinued Products
  • Primary Sclerosing Cholangitis - Product Development Milestones
  • Appendix
Back to Top